Guillain-Barre syndrome (GBS) is an autoimmune condition in which the body's immune response attacks healthy nerve cells. It leads to nerve damage causing weakness, numbness and tingling while in severe cases, it causes paralysis. As for Sinopharm's vaccine, it is still unknown if the vaccine jab or any underlying condition triggered the trial volunteer's illness.
While GBS is a rare disorder, it is not the first time that a vaccine candidate has led to the disorder. In 1976, during the mass swine flu vaccination program, GBS was noticed in around 450 people who received the shots. The vaccine drive was halted but the concerns grew over the years.
While this is the first time that a COVID-19 vaccine candidate has supposedly caused GBS symptoms, in other vaccine trials, a few have developed neurological problems. In September, a trial volunteer in AstraZeneca's COVID-19 vaccine candidate developed neurological issues and the trial had to be paused. In India, another volunteer developed a severe neurological condition. But the Serum Institute of India, behind the clinical trials, rejected the claims that the vaccine had anything to do with the patient's condition. Other vaccine candidates have had mild side-effects including fever, chills, swelling and pain at the injection site.